Fall of the mutants: T cells targeting BCR-ABL

Premal Lulla; Helen E Heslop

doi:10.1182/blood-2016-12-757336

Fall of the mutants: T cells targeting BCR-ABL

Blood. 2017 Feb 2;129(5):539-540. doi: 10.1182/blood-2016-12-757336.

Authors

Premal Lulla^{1

2

3}, Helen E Heslop^{1

2

3}

Affiliations

¹ BAYLOR COLLEGE OF MEDICINE.
² TEXAS CHILDREN'S HOSPITAL; AND.
³ HOUSTON METHODIST HOSPITAL.

Abstract

Targeting the tumor-specific junction sequence produced by the BCR-ABL fusion has long been an attractive strategy and, in this issue of Blood, Comoli et al demonstrate, for the first time in humans, clinical benefit with infusions of ^p190BCR-ABL neoantigen-specific T cells to 3 patients with active Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph⁺ ALL).

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Fusion Proteins, bcr-abl*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
T-Lymphocytes*

Substances

Fusion Proteins, bcr-abl